Literature DB >> 27475832

The Multiple Faces of Nervous System Lymphoma. Atypical Magnetic Resonance Imaging Features and Contribution of the Advanced Imaging.

María Del Mar Jiménez de la Peña1, Lidia Gómez Vicente2, Raquel Cano Alonso3, Silvia Fuertes Cabero4, Antonio Maldonado Suárez4, Vicente Martínez de Vega3.   

Abstract

Primary central nervous system lymphoma (PCNSL) is an uncommon variant of extranodal non-Hodgkin lymphoma, which involves the brain, leptomeninges, eyes, or spinal cord without evidence of systemic disease. In addition to a detailed history and physical examination, the evaluation of patients suspected of having a PCNSL should include a contrast-enhanced magnetic resonance imaging. Occassionaly, PCNSL shows peculiarities on magnetic resonance imaging, which delay the diagnosis and thus the start of treatment. It is essential that radiologists be aware of these less common presentations such as isolated spine or meningeal lymphoma, angiocentric lymphoma, ocular lymphoma, and Epstein-Barr virus-associated lymphoma. Advanced neuroimaging (diffusion and perfusion sequences, spectroscopy-magnetic resonance, and positron emission tomography metabolic imaging) are useful techniques for the differential diagnosis of PCNSL with processes such as brain glioblastoma, multiple sclerosis, and metastases and brain abscesses, especially in atypical presentations. In this article, a review of unusual radiological findings for PCNSL in immunocompetent patients is made, highlighting the usefulness of functional and metabolic imaging for establishing an early presumptive diagnosis, which reduces delays in treatment.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 27475832     DOI: 10.1067/j.cpradiol.2016.04.004

Source DB:  PubMed          Journal:  Curr Probl Diagn Radiol        ISSN: 0363-0188


  5 in total

Review 1.  Primary central nervous system lymphoma: essential points in diagnosis and management.

Authors:  Semra Paydas
Journal:  Med Oncol       Date:  2017-03-17       Impact factor: 3.064

2.  Soluble TACI and soluble BCMA as biomarkers in primary central nervous system lymphoma.

Authors:  Franziska S Thaler; Sarah A Laurent; Marion Huber; Matthias Mulazzani; Martin Dreyling; Uwe Ködel; Tania Kümpfel; Andreas Straube; Edgar Meinl; Louisa von Baumgarten
Journal:  Neuro Oncol       Date:  2017-11-29       Impact factor: 12.300

3.  A Multiplex Assay for the Stratification of Patients with Primary Central Nervous System Lymphoma Using Targeted Mass Spectrometry.

Authors:  Daniel M Waldera-Lupa; Gereon Poschmann; Nina Kirchgaessler; Omid Etemad-Parishanzadeh; Falk Baberg; Mareike Brocksieper; Sabine Seidel; Thomas Kowalski; Anna Brunn; Aiden Haghikia; Ralf Gold; Anja Stefanski; Martina Deckert; Uwe Schlegel; Kai Stühler
Journal:  Cancers (Basel)       Date:  2020-06-29       Impact factor: 6.639

4.  CXCL13 and CXCL9 CSF Levels in Central Nervous System Lymphoma-Diagnostic, Therapeutic, and Prognostic Relevance.

Authors:  Ilias Masouris; Kirsi Manz; Markus Pfirrmann; Martin Dreyling; Barbara Angele; Andreas Straube; Sigrid Langer; Marion Huber; Uwe Koedel; Louisa Von Baumgarten
Journal:  Front Neurol       Date:  2021-03-26       Impact factor: 4.003

Review 5.  Primary CNS Lymphomas: Challenges in Diagnosis and Monitoring.

Authors:  C Chiavazza; A Pellerino; F Ferrio; A Cistaro; R Soffietti; R Rudà
Journal:  Biomed Res Int       Date:  2018-06-21       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.